Abstract:Background: Side-effect of life-long immunosuppressants (IS) administration is a major obstacle for the long-term survival of pediatric liver transplantation (LT) recipients. Immunotolerance is the status that recipients discontinued IS with normal liver function and intrahepatic histology. So far, only a few clinical parameters were identified related with tolerance but failed to accurately discriminate tolerant recipients in clinical practice. Here, the authors aimed to provide a comprehensive view of pre-LT and post-LT risk factors associated with the achievement of tolerance after pediatric LT and established a tolerance predictive nomogram (ITPLT) with high accuracy and specificity. Methods: The authors enrolled 2228 pediatric recipients who received LT in Renji Hospital between October 2006 and December 2020. All participants survived over 3 years after transplantation with comprehensive and intact medical history and follow-up data. They were randomly assigned to training and validation cohorts in accordance with a ratio of 1:1. Univariate and multivariable Logistic regression were used to identify clinical factors associated with post-LT immune tolerance and establish a predictive model. The model was further validated in an independent external validation cohort from Tianjin First Central Hospital. Results: Among all participants, 6% recipients successfully tapered IS with intact allograft function. The most common reason for IS discontinuity was pneumonia. Univariate analysis identified 15 clinical factors associated with tolerance achievement, including age at LT, follow-up time, preoperative total bilirubin, creatinine, INR, CYP polymorphism, types of transplantation, massive postoperative ascites, episodes of acute rejection, and the severity of EBV and CMV infection. Using multivariable Logistic regression, the authors established the predictive ITPLT model for post-LT tolerance, which included seven easily accessible clinical factors (age at LT, CYP3A5 genotype, types of transplantation, post-LT massive ascites, preoperative INR, creatinine, and total bilirubin levels). Then, the authors visualized the model using nomogram. The c-statistics for predicting tolerance achievement in the training, internal validation, and external validation cohorts were 0.854, 0.787, and 0.746, respectively. Conclusion: Multiple pre-LT and post-LT clinical factors affected the process of immune remodeling after pediatric LT. The predictive ITPLT model, composed of seven easily accessible clinical factors, could comprehensively reveal the effect of these clinical parameters on immune remodeling and accurately identify tolerant recipients after pediatric LT. The application of ITPLT could facilitate the individualized IS strategy in the future.

Impact of early immunosuppression on pediatric liver transplant outcomes within 1 year

Impact of immunosuppression level on liver allograft fibrosis after pediatric liver transplantation: a retrospective cohort study

Current status of liver transplantation in children

Balancing immunosuppression in pediatric liver transplantation: Playing the long game

Single-drug immunosuppression is associated with noninferior medium-term survival in pediatric heart transplant recipients

Establishment and Validation of a Predictive Model of Immune Tolerance after Pediatric Liver Transplantation: a Multicenter Cohort Study

Beyond Borders: International Immunosuppression Practices in Pediatric Lung Transplantation

Immunosuppressive Therapy in Pediatric Cadaveric Renal Transplantation

Practice Variation in the Immediate Postoperative Care of Pediatric Kidney Transplantation: A National Survey

Contemporary Immunosuppression Management and 1-Year Outcomes in Dual Organ Heart Transplantation

Immunosuppression protocols for emerging oncological indications in liver transplantation: A systematic review and pooled analysis

Impact of Functional Status at the Time of Transplant on Short-Term Pediatric Lung Transplant Outcomes in the USA

Immunosuppression trends in solid organ transplantation: The future of individualization, monitoring, and management

Delayed introduction of immunosuppressive regimens in critically ill patients after liver transplantation

No Improvement in Intention-to-treat Survival and Increasing Liver Nonutilization Rate During the MELD Era

Advancing immunosuppression in liver transplantation: A narrative review

Recent contributions to transplantation at the University of Cincinnati

Long Term Survival Improved by Optimization of Immunosuppression Strategy in Renal Transplant Ecepients: a Single Center Experience

Plasma immune signatures can predict rejection-free survival in the first year after pediatric liver transplantation.

Basiliximab Induction and Postoperative Steroid-free Immunosuppression With Tacrolimus in Pediatric Liver Transplantation: A Randomized Clinical Trial

Hospitalizations for opportunistic infections following transplantation and associated risk factors: A national cohort study of Medicare beneficiaries